Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Jibeier Pharmaceutical Co (SHSE:688566) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jiangsu Jibeier Pharmaceutical Co EBITDA Margin % Related Terms
Jiangsu Jibeier Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Jibeier Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Jibeier Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Jibeier Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Jibeier Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Jibeier Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Jibeier Pharmaceutical Co (SHSE:688566) has a EBITDA Margin % of 24.55% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Jibeier Pharmaceutical Co and its competitors. This is near median its historical median of 26.23. Over the past decade, Jiangsu Jibeier Pharmaceutical Co's EBITDA Margin % has ranged from 23.28 to 33.04. According to the industry distribution chart, Jiangsu Jibeier Pharmaceutical Co ranks #207 out of 960 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Jiangsu Jibeier Pharmaceutical Co's EBITDA Margin % too high?
Jiangsu Jibeier Pharmaceutical Co's current EBITDA Margin % of 24.55% is near median its 10-year median of 26.23. Over the past 10 years, this metric has ranged from a low of 23.28 to a high of 33.04. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Jiangsu Jibeier Pharmaceutical Co's value of 24.55% is 106.6% above this industry median. Based on the distribution chart, Jiangsu Jibeier Pharmaceutical Co ranks #207 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Jibeier Pharmaceutical Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Jibeier Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Jibeier Pharmaceutical Co ranks #207 out of 960 companies for EBITDA Margin %. This places Jiangsu Jibeier Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 11.89. Jiangsu Jibeier Pharmaceutical Co's value of 24.55% is 106.6% above this benchmark. Historically, Jiangsu Jibeier Pharmaceutical Co's own EBITDA Margin % has ranged from 23.28 to 33.04 over the past decade. While the company's 10-year median is 26.23 vs. the industry median of 11.89, Jiangsu Jibeier Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Jibeier Pharmaceutical Co's current EBITDA Margin % of 24.55% is 106.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Jibeier Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Jibeier Pharmaceutical Co's current EBITDA Margin % is 24.55%, which is near median its own 10-year median of 26.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Jibeier Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Jibeier Pharmaceutical Co (SHSE:688566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥33.80, compared to a current price of ¥25.72 — trading 23.9% below its estimated fair value. The current EBITDA Margin % is 24.55%, which is near median its 10-year median of 26.23 and 106.6% above the Drug Manufacturers industry median of 11.89. Jiangsu Jibeier Pharmaceutical Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jiangsu Jibeier Pharmaceutical Co (SHSE:688566), the current EBITDA Margin % is 24.55% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Jibeier Pharmaceutical Co (SHSE:688566) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Jibeier Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥25.72 is trading 23.9% below its estimated GF Value™ of ¥33.80.
GuruFocus considers Jiangsu Jibeier Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688566:
EBITDA Margin %: 24.55% (near median its 10-year median of 26.23)
GF Value™: ¥33.80 vs. price of ¥25.72 (23.9% below fair value)
Industry Position: 106.6% above the Drug Manufacturers median (#207 of 960)
No single metric tells the full story. See the SHSE:688566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Jibeier Pharmaceutical Co Ltd specializes in the research, development, production and sales of chemical preparations, proprietary Chinese medicine preparations, and bulk medicines. The company's products include tablets, hard capsules, eye drops, and gels, agents, creams and other dosage. Its products are used in various application fields such as Cardiovascular drugs, Blood system drugs, Immune system drugs, Ophthalmic drugs, Antipyretic and analgesic drugs, Respiratory medicine, and other.
84GF Score
Get the complete analysis for SHSE:688566
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688566 has been successfully added to your 
